{"filing":{"accession_number":"0001193125-26-359185","cik":"0001785530","ticker":"HOWL","company_name":"Werewolf Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-14","primary_document":"d141219d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/d141219d8k.htm"},"events":[{"id":28853,"run_id":26407,"accession_number":"0001193125-26-359185","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Werewolf Therapeutics entered into a material asset purchase agreement with EMD Serono on August 14, 2026, selling its INDUCER and INDUKINE platforms for $28.0 million upfront plus $5.0 million upon technology transfer completion. This constitutes a material disposition of assets under Item 1.01, with significant intellectual property and pre-clinical compounds transferred, while the company retains development rights for WTX-124 and WTX-330 clinical programs through a concurrent exclusive license agreement.","company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30915,"accession_number":"0001193125-26-359185","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Werewolf Therapeutics entered into a material asset purchase agreement with EMD Serono on August 14, 2026, selling its INDUCER and INDUKINE platforms for $28.0 million upfront plus $5.0 million upon technology transfer completion. This constitutes a material disposition of assets under Item 1.01, with significant intellectual property and pre-clinical compounds transferred, while the company retains development rights for WTX-124 and WTX-330 clinical programs through a concurrent exclusive license agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:09:07.737404+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30915,"accession_number":"0001193125-26-359185","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Werewolf Therapeutics entered into a material asset purchase agreement with EMD Serono on August 14, 2026, selling its INDUCER and INDUKINE platforms for $28.0 million upfront plus $5.0 million upon technology transfer completion. This constitutes a material disposition of assets under Item 1.01, with significant intellectual property and pre-clinical compounds transferred, while the company retains development rights for WTX-124 and WTX-330 clinical programs through a concurrent exclusive license agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T20:09:07.737404+00:00","company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","filing_date":"2026-08-20"}]}